- Home
- Primary Care
- Dual TNF/OX40L Inhibition with Brivekimig in Moderate-to-Severe Hidradenitis Suppurativa: Synopsis of the HS-OBTAIN Phase 2a Trial

2w3 min read
Medical Article
Introduction Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease characterized by painful abscesses, nodules, and draining tunnels, often leading to morbidity, scarring, and reduced quality of life (1). Treatment options remain limited, particularly in biologic-naïve moderate-to-severe disease (1). Adalimumab (anti-TNF) is approved

Dual TNF/OX40L Inhibition with Brivekimig in Moderate-to-Severe Hidradenitis Suppurativa: Synopsis of the HS-OBTAIN Phase 2a Trial
59 Reached1 Comments
Similar Content

Woman presented with Fever of Unknown Origin
7725 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes

Rubella Syndrome in Neonate
1400 Reached12 Comments9 Likes

Pregnant Woman with HIV-1 Infection
747 Reached1 Likes

Use of Clindamycin for Managing Bacterial Vaginosis
11195 Reached29 Comments8 Likes